Industry News
Stay in the know with ASTRO’s Corporate Members!
Staying up to date with ASTRO's Corporate Members has never been easier! Now ASTRO members can find press releases and announcements surrounding industry involved with radiation oncology on ASTRO’s new industry webpage.
January 13, 2025
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).
January 10, 2025
RapidArc Dynamic in Head and Neck Applications: Smarter, Faster and More Conformal
(Varian, a Siemens Healthineers company webinar)
Thursday, January 30, 2025
7:00 a.m. Pacific time |10:00 a.m. Eastern time | 16:00 Central Europe
Presented by: Eva Onjukka, PhD – Associate Professor – Karolinska University Hospital
Don’t miss this webinar where Karolinska Institute provides a deep dive into the advanced capabilities of RapidArc Dynamic for Head and Neck (HN) applications. Discover how innovative algorithms driving dynamic collimator movements and modulated ports within a single arc enhance treatment planning and delivery. This session combines scientific expertise with practical strategies, offering insights to optimize organ-at-risk sparing, reduce delivery times and ensure robust treatment planning — surpassing traditional VMAT techniques.
After viewing this webinar, participants should be able to:
- Gain a comprehensive understanding of RapidArc Dynamic for head and neck applications focusing on its advanced algorithms, dynamic collimator and modulated ports, and their contributions to treatment delivery and planning innovation
- Recognize how to leverage the new degrees of freedom in RapidArc Dynamic to spare organs at risk and/or reduce delivery time, illustrated through diverse clinical examples
- Evaluate the robustness of RapidArc Dynamic for head and neck applications using complexity metrics and verification measurements
- Identify essential considerations and develop effective QA strategies for RapidArc Dynamic
VARIAN and RAPIDARC are trademarks of Varian Medical Systems, Inc., pending or registered U.S. Pat. & Tm. Off.
January 10, 2025
An Analytics Masterclass on DaaS
(Varian, a Siemens Healthineers company webinar)
Friday, January 24, 2025
8:00 a.m. Pacific time |11:00 a.m. Eastern time | 17:00 Central Europe
Presented by: Travis Dwyer – Data Analyst – Alliance Cancer Care
This isn't your typical product demo. Travis Dwyer of Alliance Cancer Care will share how he has put InSightive Gen2 Data as a Service (DaaS) to work for himself and his clinic to tackle real business and data problems and extract practical insights. Hear actual stories, practical tips and valuable wisdom directly from the frontlines. InSightive Gen2 Data as a Service (DaaS) is a cloud-native, oncology-specific, analytics solution that helps clinic professionals turn raw data into actionable insights for faster, more effective decision making.
After viewing this webinar, participants should be able to:
- Identify high-value opportunities where InSightive Gen2 Data as a Service can solve unique analytics challenges
- Explain strategies for leveraging pre-connected data models to accelerate analytics projects
- Get ideas for potential time and resource savings in your own analytics projects
VARIAN and INSIGHTIVE are trademarks of Varian Medical Systems, Inc., pending or registered U.S. Pat. & Tm. Off.
December 12, 2024
Novocure has announced positive topline results from the pivotal Phase 3 PANOVA-3 clinical trial
Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control. PANOVA-3 evaluated the use of Tumor Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.
October 30, 2024
Gilead Oncology invites you to an upcoming webinar “A New Lens on Lung Cancer: Infusing Lung Cancer Conversations with HIV Learnings.”
In recognition of Lung Cancer Awareness Month, this event will bring together patients, caregivers, and other experts in the field to discuss fostering a more empathetic and informed approach to lung cancer. The webinar will be hosted by Gilead in partnership with Gryt Health and is scheduled for Thursday, November 21, at 12:00 p.m. Eastern time.
Here’s what you can expect:
Webinar Title: A New Lens on Lung Cancer: Infusing Lung Cancer Conversations with HIV Learnings
Date: Thursday, November 21
Time: 12:00 p.m. Eastern time | 9:00 a.m. Pacific time
Description: Shame and blame linked to lung cancer can lead to depression, discrimination, reduced quality of life and delays in screening, diagnosis and care. Gilead and Gryt Health are calling on all of us to help change the dialogue. During this webinar, you will hear from a panel of speakers, including patients, caregivers and advocates. The conversation will explore the critical and persistent challenges the lung cancer community faces and how we can apply lessons from the HIV community to foster a more empathetic and informed approach to this complex illness.
To secure your spot for this webinar, please register here.
October 30, 2024
Novocure Reports Third Quarter 2024 Financial Results
Novocure announced that the U.S. FDA has granted Breakthrough Device designation for the use of TTFields therapy for brain metastases from non-small cell lung cancer.
September 26, 2024
RICOH 3-D for Healthcare and Kallisio partner to enhance radiation oncology care with Stentra™ oral stent
EXTON, PA, September 26, 2024 Ricoh USA, Inc. and Kallisio today announced a strategic partnership to manufacture and distribute Stentra™, a 510(k)-cleared, patient-specific oral stent designed to improve radiation therapy for head and neck cancer (HNC) patients. Developed using technology exclusively licensed from MD Anderson Cancer Center, Stentra™ is engineered to protect healthy tissue by precisely displacing and immobilizing sensitive areas during treatment, allowing for more targeted and effective radiation delivery. This innovation is crucial in minimizing side effects and enhancing overall treatment outcomes. Read full press release.
